Broadly speaking, this strategy can be considered for stage IA mycosis fungoides, primary cutaneous CD4+ small/medium pleomorphic T-cell lymphomas, and subcutaneous panniculitis-like T-cell lymphomas with no symptoms. This evidence concerns the gene CD4 and mycosis fungoides.